NCAM1 and acute myeloid leukemia: Although the applicability of CD19-directed CAR-T therapy in acute myeloid leukemia (AML) is limited, alternative leukemic cell-specific antigens such as CD33, CD38, CD56, CD117, CD123, Lewis-Y, and Muc-1 are currently being explored [85].